Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease

  • Authors: Judith S. Currier, MD, MSc; Risa Hoffman, MD, MPH (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/10/18 (What's New)


  • Patients on lipid-lowering therapy should have fasting lipids monitored 6-12 weeks after therapy initiation and at similar intervals following dose increases
    • Once stable, monitor every 6-12 months
  • Use of support staff such as nutrition counselors or dieticians may be helpful

Action required